Study details
Enrolling now
A Prospective Clinical Trial to Evaluate Xcell Amnio MatrixTM (XAM) in Managing Chronic Non-healing DFUs
New Horizon Medical Solutions
NCT IDNCT07116174ClinicalTrials.gov data as of Apr 2026
Target enrollment
108
Study length
about 1 year
Ages
18+
Locations
3 sites in CA, TX
About this study
This trial is testing whether applying Xcell Amnio MatrixTM (XAM) as an adjunct to standard care helps heal chronic non-healing diabetic foot ulcers. Participants will receive XAM weekly for 12 weeks and be followed up after treatment.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Xcell Amnio Matrix
- 2.Take Standard of Care (SOC)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low13%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Secondary: Change in pain in the target ulcer assessed using the Numerical Pain Rating Scale (NPRS) during the 12 weeks of the Treatment Phase.